Skip to main content
SpringerLink
Log in

Adnexe

  • Chapter
Book cover Die Gynäkologie

Zusammenfassung

Ovarialtumoren stellen eine heterogene Gruppe verschiedener histologischer Tumorentitäten dar. Neben der Unterscheidung zwischen Zysten und echten Neoplasien erfolgt die Einteilung anhand des histologischen Ursprungs. Dabei werden epitheliale Tumoren von Stromatumoren und Keimzelltumoren unterschieden. Alle echten Neoplasien des Ovars werden in gut- und bösartige Tumoren eingeteilt. Bei den epithelialen Neubildungen werden zusätzlich jene mit niedrig malignem Potenzial, sog. Borderline- Tumoren abgegrenzt.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 199.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Alcazar JL, Merce LT, Laparte C et al. (2003) A new scoring system to differentiate benign from malignant adnexal masses. Am J Obstetric Gynecol 237: 163–167

    Google Scholar 

  • Bastert G (1996) Spezielle gynäkologische Onkologie II. In: Klinik der Frauenheilkunde und Geburtshilfe, Bd 12. Urban & Schwarzenberg: 1110

    Google Scholar 

  • Bertelsen K (1990) Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study. Gynecol Oncol 38 (2): 203209

    Article  Google Scholar 

  • Borgfeldt C, Andolf E (2004) Cancer risk after hospital discharge diagnosis of benign ovarian cysts and endometriosis. Acta Obstet Gynecol Scand 83: 395–400

    PubMed  Google Scholar 

  • Bowman A, Gabra H, Langdon SP, Lessells A, Stewart M, Young A, Smyth JF (2002 ) CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin Cancer Res 8 (7): 2233–2239

    PubMed  CAS  Google Scholar 

  • Brinton LA, Lamb EJ, Moghissi KS et al. (2004) Cancer risk after the use of ovulation-stimulating drugs. Obstetr Gynecol Surv 59 (9): 657– 659

    Article  Google Scholar 

  • Bristow RE, Lagasse LD, Karlan BY (1996) Secondary surgical cytoreduction for advanced epithelial ovarian cancer. Cancer 78: 2049– 2062

    Article  PubMed  CAS  Google Scholar 

  • Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 1; 20 (5): 1248–1259

    Google Scholar 

  • Burger RA, Brady MF, Bookman MA et al. (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365: 2473–2483

    Article  PubMed  CAS  Google Scholar 

  • Burges A, Wimberger P, Kümper C et al. (2007) Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study. Clin Cancer Res 13 (13): 3899–3905

    Article  PubMed  CAS  Google Scholar 

  • Castillo G, Alcazar JL, Jurado M (2004) Natural history of sonographically detected simple unilocular adnexal cysts in asymptomatic postmenopausal women. Gynecol Oncol 92: 965–969

    Article  PubMed  Google Scholar 

  • Chan JK, Lin YG, Loizzi V et al. (2003) Borderline ovarian tumors in reproductive- aged women: fertility-sparing surgery and outcome. J Reprod Med 48: 756–760

    PubMed  Google Scholar 

  • Clarke-Pearson D (2009) Screening for ovarian cancer. N Engl J Med 361: 170–177

    Article  PubMed  CAS  Google Scholar 

  • Czernobilsky B (1997) What's new in ovarian serous borderline tumors. Pathol Res Pract 193: 735–739

    Article  PubMed  CAS  Google Scholar 

  • Du Bois A, Schmalfeldt B, Meier W, Sehouli J, Pfisterer J; Arbeitsgemeinschaft Gynäkologische Onkologie (AGO); Kommission OVAR; AGO Study Group Ovarian Cancer (AGO-OVAR); Norddeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO) (2006) Ovarian cancer–can intraperitoneal therapy be regarded as new standard in Germany? Int J Gynecol Cancer 2006 6 (5): 1756–1760

    Google Scholar 

  • Du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials. Cancer 115 (6):1234–1244

    Article  Google Scholar 

  • Du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 115 (6): 1234–1244

    Article  Google Scholar 

  • Gilks CB, Alkushi A, Yue JJW et al. (2002) Advanced-stage serous borderline tumors of the ovary: a clinicopathological study of 49 cases. Int J Gynecol Pathol 22: 29–36

    Article  Google Scholar 

  • Hanker LC, Kaufmann M (2009) Seltene gynäkologische Tumoren. Onkologe 15: 261–269

    Article  Google Scholar 

  • Harter P, Hilpert F, Mahner S, Kommoss S, Heitz F, du Bois A (2009) Role of cytoreductive surgery in recurrent ovarian cancer. Expert Rev Anticancer Ther 9 (7): 917–922

    Article  PubMed  Google Scholar 

  • Kindermann G, Maassen V, Kuhn W (1995a) Laparoscopic preliminary surgery of ovarian malignancies. Experiences from 127 German gynecologic clinics. Geburtsh Frauenheilkd 55 (12): 687–694

    Article  CAS  Google Scholar 

  • Kindermann G, Maaßen V, Kuhn W (1995b) Laparoskopisches »Anoperieren « von ovariellen Malignomen. Geburtsh Frauenheilkd 12: 687694

    Google Scholar 

  • Kuhn W, Jänicke F, Pache L et al. (1993) Entwicklung in der Therapie des fortgeschrittenen Ovarialkarzinoms FIGO III. Geburtsh u Frauenheilk 53: 293–302

    Article  CAS  Google Scholar 

  • Kuhn W, Schmalfeldt B, Reuning U et al. (1999) Prognostic significance of urokinase (uPA) and ist inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br J Cancer 79: 1746–1751

    Article  PubMed  CAS  Google Scholar 

  • Le T, Leis A, Pahwa P, Wright K et al. (2003) Quality-of-life issues in patients with ovarian cancer and their caregivers: a review. Obstetr Gynecol Surv 58 (11): 749–758

    Article  CAS  Google Scholar 

  • Mahner S, Baasch C, Schwarz J, Hein S, Wölber L, Jänicke F, Milde- Langosch K (2008) C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma. Br J Cancer 99 (8): 1269–1275

    Article  PubMed  CAS  Google Scholar 

  • Mais V, Ajossa S, Mallarini G et al. (2003) No recurrence of mature ovarian teratomas after laparoscopic cystectomy. Obstet Gynecol 101: 11681171

    Google Scholar 

  • Markmann M, Hoskins WJ (eds) (1993) Cancer of the ovary. New York: Raven Obeidat B, Latimer J (2004) Can optimal primary cytoreduction be predicted in advanced-stage epithelial ovarian cancer? Obstetr Gynecol Surv 59 (10): 709–711

    Google Scholar 

  • Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R (2003) Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 1; 21 (17): 3194–200

    Google Scholar 

  • Panici PB, Maggioni A, Hacker N et al. (2005) Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst 97 (8): 560–566

    Article  PubMed  Google Scholar 

  • Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Trope C; ICON and AGO Collaborators (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 21; 361 (9375): 2099–2106

    Google Scholar 

  • Pectasides D, Pectasides E, Kassanos D (2008) Germ cell tumors of the ovary. Cancer Treat Rev 34: 427–441

    Article  PubMed  CAS  Google Scholar 

  • Perren TJ, Swart AM, Pfisterer J et al. (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365: 2484–2496

    Article  PubMed  CAS  Google Scholar 

  • Pfisterer J, Plante M, Vergote I, du Bois A et al.; AGO-OVAR; NCIC CTG; EORTC GCG (2009) Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24 (29): 4699–4707 [epub 2006 Sep 11]

    Google Scholar 

  • Pujade-Lauraine E, Mahner S, Kaern J et al. (2009) A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG). J Clin Oncol 27: LB A5509

    Google Scholar 

  • Risum S, Høgdall C, Markova E, Berthelsen AK, Loft A, Jensen F, Høgdall E, Roed H, Engelholm SA (2009) Influence of 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography on recurrent ovarian cancer diagnosis and on selection of patients for secondary cytoreductive surgery. Int J Gynecol Cancer 19 (4):600–604

    Article  PubMed  Google Scholar 

  • Ruckhäberle E, Rody A, Hanker L, Kriener S, Kaufmann M, Gätje R (2007) Ovarialkarzinom nach Ovariektomie – selten aber möglich! Geburtsh Frauenheilkd 67: 764–766

    Article  Google Scholar 

  • Rustin GJ, van der Burg ME, Griffin CL, and the EORTC 55955 investigators (2010) Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 376 (9747): 1155–1163

    Google Scholar 

  • Schilder JM, Thompson AM, DePriest PD et al. (2002) Outcome of reproductive age women with stage IA or ic invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol 87: 1–7

    Article  PubMed  Google Scholar 

  • Sevin BU (1991) Operative Behandlung des Karzinoms der Ovarien und der Tuben. In: Zander J, Graeff H (Hrsg) Gynäkologische Operationen, Kirschnersche Operationslehre, Bd 9, 3. Aufl. Springer, Berlin Heidelberg New York, S 317–334

    Google Scholar 

  • Sohn C, Krapfl-Gast AS, Schiesser M (1998) Sonographie in Gynäkologie und Geburtshilfe. In: Checklisten der Medizin. Stuttgart: Thieme: 177

    Google Scholar 

  • Stegner HE (1994) Pathologie der weiblichen Genitalorgane II. In: Doerr, Seifert, Uehlinger (Hrsg) Spezielle pathologische Anatomie, Bd 20/II. Berlin Heidelberg New York: Springer

    Google Scholar 

  • Thigpen J, Blessing JA, DeGeest K et al. (2004) Cisplatin as initial chemotherapy in ovarian carcinosarcomas: a gynecologic oncology group study. Obstetr Gynecol Surv 59 (8): 589–590

    Article  Google Scholar 

  • Trillsch F, Mahner S, Ruetzel J, Harter P, Ewald-Riegler N, Jaenicke F, du Bois A (2010) Clinical management of borderline ovarian tumors. Expert Rev Anticancer Ther 10 (7): 1115–1124

    Article  PubMed  CAS  Google Scholar 

  • Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N, Vermorken JB, Torri V, Mangioni C, Pecorelli S, Lissoni A, Swart AM (2003) International Collaborative Ovarian Neoplasm 1; European Organisation for Research and Treatment of Cancer Collaborators – adjuvant chemotherapy in Ovarian Neoplasm. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant chemotherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with earlystage ovarian carcinoma. J Natl Cancer Inst 15, 95 (2): 105–112

    Google Scholar 

  • van der Burg M, van Lent M, Buyse M et al. (1995) The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 332: 629–634

    Article  PubMed  Google Scholar 

  • Wölber L, Jung S, Eulenburg C et al. (2010) Perioperative morbidity and outcome of secondary cytoreduction for recurrent epithelial ovarian cancer. Eur J Surg Oncol (EJSO) 36 (6): 583–588

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Gynäkologie Onkologie und Brustzentrum, Asklepios Klinik Nord-Heidberg, Tangstedter Landstraße 400, 22417, Hamburg

    Prof. Dr. med. J. Schwarz

  2. Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg

    Priv.-Doz. Dr. med. S. Mahner & Prof. Dr. med. F. Jänicke

Authors
  1. Prof. Dr. med. J. Schwarz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Priv.-Doz. Dr. med. S. Mahner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Prof. Dr. med. F. Jänicke
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Johann-Wolfgang-Goethe-Universität Frankfurt, Universitätsfrauenklinik, Frankfurt

    Manfred Kaufmann

  2. Otto-von-Guericke-Universität Magdeburg, Universitätsfrauenklinik, Magdeburg

    Serban D. Costa

  3. Friedrich-Alexander-Universität Erlangen-Nürnberg, Klinikum St. Marien, Lehrkrankenhaus der Universität Regensburg, Erlangen-Nürnberg

    Anton Scharl

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Schwarz, J., Mahner, S., Jänicke, F. (2013). Adnexe. In: Kaufmann, M., Costa, S.D., Scharl, A. (eds) Die Gynäkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-20923-9_30

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-20923-9_30

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-20922-2

  • Online ISBN: 978-3-642-20923-9

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation